Page 502 - ஒன்றுபட்டது மாநிலங்களில் பத்திரங்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
老同志也不能不講武德-財經新聞-新浪新聞中心
sina.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.tw Daily Mail and Mail on Sunday newspapers.
資深學者張非魚：總結債券市場經驗教訓 防止以訛傳訛
sina.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.tw Daily Mail and Mail on Sunday newspapers.
老同志也不能不講武德-財經新聞-新浪新聞中心
sina.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.tw Daily Mail and Mail on Sunday newspapers.
Santa Fe Gold Announces Plan to Resume Trading
Santa Fe Gold Announces Plan to Resume Trading
ALBUQUERQUE, N.M., Dec. 18, 2020 Santa Fe Gold Corporation (OTC PINK: SFEG), (the “Company”) announced today that it is continuing to proceed with its plan to resume regular trading. The Company, because of not being current in its filings, was notified by the Securities & Exchange Commission (the “Commission”) that it was seeking de-registration of our common stock under Section 12 of the Securities Exchange Act of 1934 (the “Exchange Act”). The Company determined that the most expedient path was to settle with the Commission, agree to de-register our common stock (rather than spend the time and resources in litigating the matter), file a Form 10 registration statement to re-register our common stock under the Exchange Act, and work with a sponsor broker dealer to update our Form 15c-211 with FINRA. What transpired yesterday in the form of a trading halt was the result of th
Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
ORGOVYX demonstrated a 96.7% response rate in testosterone suppression to castrate levels ( 50 ng/dL) through 48 weeks in the Phase 3 HERO study
Conference call and webcast to be held on December 21 at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time
BASEL, Switzerland, Dec. 18, 2020 (GLOBE NEWSWIRE) Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that the U.S. Food and Drug Administration (FDA) has approved ORGOVYX™ (relugolix) for the treatment of adult patients with advanced prostate cancer. ORGOVYX, which was granted Priority Review by the FDA, is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist for men with advanced prostate cancer. The approval is based on efficacy and safety data from